- Recommendation ID
- TA404/1
- Question
Further research is recommended to resolve uncertainties about the clinical effectiveness of degarelix compared with luteinising hormone-releasing hormone (LHRH) agonists such as leuprorelin, goserelin and triptorelin for treating advanced hormone-dependent prostate cancer, particularly in subgroups of people with preexisting cardiovascular disease, people with skeletal (including spinal) metastases and people with impending ureteric and urethral obstruction. Research should be planned as part of well-conducted randomised clinical trials.
- Any explanatory notes
(if applicable) None
Source guidance details
- Comes from guidance
- Degarelix for treating advanced hormone-dependent prostate cancer
- Number
- TA404
- Date issued
- August 2016
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 31/08/2016 |